ResearchMoz

Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive Towards Personalized Treatment and Market Growth

GBI Research
Published Date » 2014-02-06
No. Of Pages » 76
   
 GBI Research has released its pharma report “Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive Towards Personalized Treatment and Market Growth.” The value of the Cystic Fibrosis (CF) market is expected to increase significantly in value over the forecast period across the leading eight developed nations, from $695.6 million in 2012 to almost $4.5 billion in 2019. This equates to a Compound Annual Growth Rate (CAGR) of 30.4%. Novel treatments with disease-modifying mechanisms of action are the primary factor driving the growth of the value of the market. The positive impact of new market entrants will offset the effects of key patent losses during the forecast period.  
   
 Cystic Fibrosis Transmembrane conductance...
TABLE OF CONTENT

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Diagnosis
2.6 Prognosis
2.7 Assessment of Disease Severity
2.8 Treatment

3 Marketed Products
3.1 Overview
3.2 Product Profiles
3.2.1 Pulmozyme (dornase alfa) – Genentech
3.2.2 Bronchitol (mannitol) – Pharmaxis
3.2.3 TOBI (tobramycin) – Novartis
3.2.4 TOBI Podhaler (tobramycin) – Novartis
3.2.5 Bramitob/Bethkis (tobramycin) – Chiesi Farmaceutici
3.2.6 Colobreathe (colistimethate sodium) – Forest Laboratories
3.2.7 Cayston (aztreonam) – Gilead Sciences
3.2.8 Kalydeco (ivacaftor) – Vertex Pharmaceuticals
3.2.9 Pancreatic Enzyme Replacement Therapies
3.2.10 Other Successful Products
3.3 Heat Map of Marketed Products
3.4 Conclusion

4 Developmental Pipeline
4.1 Overview
4.2 Mechanisms of Action in the Pipeline
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Clinical Trial Duration
4.3.3 Clinical Trial Size
4.4 Promising Pipeline Molecules
4.4.1 Lumacaftor (VX809) – Vertex Pharmaceuticals
4.4.2 Ataluren (PTC124) – PTC Therapeutics
4.4.3 Aeroquin (levofloxacin) – Aptalis Pharma
4.4.4 Arikace (amikacin liposomal) – Insmed
4.4.5 Other Promising Molecules
4.5 Heat Map of Pipeline Products
4.6 Conclusion

5 Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Global Markets
5.1.2 North America
5.1.3 Top Five EU Countries
5.2 Drivers and Barriers
5.2.1 Drivers
5.2.2 Barriers

6 Strategic Consolidations
6.1 Major Co-Development Deals
6.2 Major Licensing Deals

7 Appendix
7.1 References
7.1.1 Marketed Product Heat Map References
7.1.2 Pipeline Product Heat Map References
7.2 Market Definition
7.3 Abbreviations
7.4 Methodology
7.5 Coverage
7.6 Secondary Research
7.7 Therapeutic Landscape
7.8 Epidemiology-Based Forecasting
7.9 Market Size by Geography
7.10 Geographical Landscape
7.11 Pipeline Analysis
7.12 Competitive Landscape
7.12.1 Expert Panel Validation
7.13 Contact Us
7.14 Disclaimer

List of Tables


Table 1: Cystic Fibrosis Market, Global, Treatment Plan
Table 2: Cystic Fibrosis Market, Global, Pipeline, Preclinical
Table 3: Cystic Fibrosis Market, Global, Pipeline, Phase I
Table 4: Cystic Fibrosis Market, Global, Pipeline, Phase II
Table 5: Cystic Fibrosis Market, Global, Pipeline, Phase III
Table 6: Cystic Fibrosis Market, Global, Pipeline, Pre-Registration
Table 7: Cystic Fibrosis Market, Global, Pipeline, Undisclosed
Table 8: Cystic Fibrosis Market, Global, Market Forecast, 2012-2019
Table 9: Cystic Fibrosis Market, US, Market Forecast, 2012-2019
Table 10: Cystic Fibrosis Market, Canada, Market Forecast, 2012-2019
Table 11: Cystic Fibrosis Market, UK, Market Forecast, 2012-2019
Table 12: Cystic Fibrosis Market, France, Market Forecast, 2012-2019
Table 13: Cystic Fibrosis Market, Germany, Market Forecast, 2012-2019
Table 14: Cystic Fibrosis Market, Italy, Market Forecast, 2012-2019
Table 15: Cystic Fibrosis Market, Spain, Market Forecast, 2012-2019

List of Figures


Figure 1: Cystic Fibrosis Market, Global, Marketed, Heat Map
Figure 2: Cystic Fibrosis Market, Global, Pipeline Summary
Figure 3: Cystic Fibrosis Market, Global, Pipeline Mechanisms of Action
Figure 4: Cystic Fibrosis Market, Global, Clinical Trial Failure Rate
Figure 5: Cystic Fibrosis Market, Global, Pipeline Trial Duration
Figure 6: Cystic Fibrosis Market, Global, Pipeline, Trial Duration by Mechanism of Action
Figure 7: Cystic Fibrosis Market, Global, Pipeline Trial Size
Figure 8: Cystic Fibrosis Market, Global, Pipeline, Trial Size by Mechanism of Action
Figure 9: Cystic Fibrosis Market, Global, Pipeline, Promising Pipeline Products, Lumacaftor Forecast,
2015-2019
Figure 10: Cystic Fibrosis Market, Global, Pipeline, Promising Pipeline Products, Ataluren Forecast,
2016-2019
Figure 11: Cystic Fibrosis Market, Global, Pipeline Promising Pipeline Products, Aeroquin Forecast,
2014-2019
Figure 12: Cystic Fibrosis Market, Global, Pipeline, Promising Pipeline Products, Arikace Forecast,
2015-2019
Figure 13: Cystic Fibrosis Market, Global, Pipeline, Heat Map
Figure 14: Cystic Fibrosis Market, Global, Treatment Patterns, 2012–2019
Figure 15: Cystic Fibrosis Market, Global, Market Size, 2012–2019
Figure 16: Cystic Fibrosis Market, North America, Treatment Patterns, 2012–2019
Figure 17: Cystic Fibrosis Market, North America, Annual Cost of Treatment, 2012–2019
Figure 18: Cystic Fibrosis Market, North America, Market Size, 2012–2019
Figure 19: Cystic Fibrosis Market, Top Five EU Countries, Treatment Patterns, 2012–2019
Figure 20: Cystic Fibrosis Market, Top Five EU Countries, Annual Cost of Treatment, 2012–2019
Figure 21: Cystic Fibrosis Market, Top Five EU Countries, Market Size, 2012–2019
Figure 22: Cystic Fibrosis Market, Global, Major Co-developments by Region and Value, 2006–2013
Figure 23: Cystic Fibrosis Market, Global, Major Co-development Deals by Year, 2006–2013
Figure 24: Cystic Fibrosis Market, Global, Co-development Deals by Phase, 2006–2013
Figure 25: Cystic Fibrosis Market, Global, Licensing Deals by Region, 2006–2013
Figure 26: Cystic Fibrosis Market, Global, Licensing Deals by Year, 2006–2013
Figure 27: Cystic Fibrosis Market, Global, Licensing Deals by Phase, 2006–2013
Figure 28: Forecasting Model for Therapeutic Areas

Upcoming Reports:

Furandicarboxylic Acid Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Furandicarboxylic acid (FDCA) is an oxidized furan derivative of carboxylic acid. It is a very stable compound with a huge potential for various applications. It is a bio-based substitute for carboxylic acid and other petroleum based products for synthesis of a wide variety of plastics. Furandicarboxylic acid finds future prospect, as a biobased material, in market for the manufacture of polyesters, polyamides, thermosets, resins, plasticizers, polyurethanes and a wide range of solvents. However, lack of any feasible, commercially economical production process is the final hurdle that...
Medical Nonwoven Disposables Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Medical nonwoven disposables are important products in the global healthcare industry as they provide hygiene benefits over the woven fabrics. Woven fabrics used in hospitals, clinics and physician offices are vulnerable to hospital acquired infections (HAIs) and other infections such as AIDs and hepatitis. Medical nonwoven disposables prevent transmission of these infections to some extent since they are soon disposed of. Therefore, the increasing awareness about these infections and efforts to control these infections are driving the global market for medical nonwoven disposables...
Chlor-Alkali Market - Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast, 2013 - 2019
By - Transparency Market Research
Chlor alkali refers to an industrial process used for producing caustic soda, chlorine, and other chlorine and sodium based products or derivatives like hydrochloric acid, chlorinated paraffin, sodium hypochlorite, bleaching powder, and hydrogen gas. The process involves the electrolysis of brine (sodium chloride) solution resulting in the formation of the above-mentioned products. The main products of the chlor alkali market are chlorine gas, caustic soda (sodium hydroxide), and soda ash (sodium carbonate). The chlor alkali market is primarily segregated based on the product type....

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Order cancellations not a sign of market slump: Airbus
Jul 31, 2014  
Leading aircraft manufacturer Airbus on Wednesday said that the recent wave of order cancellations for its commercial jetliners do not mean that the market has declined. The market is still strong and single-aisle jets deals are likely to return later. A total of 225 Airbus cancellations were reported since the beginning of this year. Of these, Dubai’s Emirates Airlines alone...
Leading Australian Universities Want to Hike Fees, Enroll Fewer Students
Jul 31, 2014  
Australia’s prestigious group of top eight universities, also known as the Group of Eight (Go8), has indicated plans of increasing tuition fees while reducing the number of students they enroll, a reform-backer has predicted. These decisions could be made if the universities are deregulated .  Arguing for this decision, the chairman of Go8, and vice chancellor of the ANU, Ian...
Blackstone Invests $800 Million in Asian Oil-Based Energy Company
Jul 31, 2014  
Blackstone Energy Partners announced to invest $800 million in an Asian based energy company that is led by former industry executives.  Blackstone is popularly considered a part of the world’s largest administrator of alternatives to financial stocks and bonds. New York-based managing director, Angelo Acconcia of Blackstone Energy Partners said in an interview that Tamarind...
Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...